572 related articles for article (PubMed ID: 20574659)
21. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
22. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.
Fulham MJ; Carter J; Baldey A; Hicks RJ; Ramshaw JE; Gibson M
Gynecol Oncol; 2009 Mar; 112(3):462-8. PubMed ID: 19150121
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Tekinsoy B; Salepci T; Gumus M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
[TBL] [Abstract][Full Text] [Related]
24. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
25. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
[TBL] [Abstract][Full Text] [Related]
26. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
[TBL] [Abstract][Full Text] [Related]
27. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
28. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
Kim CK; Park BK; Choi JY; Kim BG; Han H
J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
30. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
31. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.
Picchio M; Sironi S; Messa C; Mangili G; Landoni C; Gianolli L; Zangheri B; Viganò R; Aletti G; De Marzi P; De Cobelli F; Del Maschio A; Ferrari A; Fazio F
Q J Nucl Med; 2003 Jun; 47(2):77-84. PubMed ID: 12865867
[TBL] [Abstract][Full Text] [Related]
32. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
34. [The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma].
Grabiec M; Walentowicz M; Nowicki P
Ginekol Pol; 2006 Oct; 77(10):746-52. PubMed ID: 17219805
[TBL] [Abstract][Full Text] [Related]
35. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
[TBL] [Abstract][Full Text] [Related]
36. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
37. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Morita S; Suganuma N; Sugimura K
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):362-72. PubMed ID: 18931841
[TBL] [Abstract][Full Text] [Related]
38. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Takekuma M; Maeda M; Ozawa T; Yasumi K; Torizuka T
Int J Clin Oncol; 2005 Jun; 10(3):177-81. PubMed ID: 15990965
[TBL] [Abstract][Full Text] [Related]
40. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]